Manuela Porru

Research output

Research output per year 2016 2020

• 19 Article
• 3 Review article
• 1 Chapter

Research output per year

Research output per year

Search results

• 2020

  Circulating miRNAs in small extracellular vesicles secreted by a human melanoma xenograft in mouse brains

  Guglielmi, L., Nardella, M., Musa, C., Cifola, I., Porru, M., Cardinali, B., Iannetti, I., Di Pietro, C., Bolasco, G., Palmieri, V., Vilardo, L., Panini, N., Bonaventura, F., Papi, M., Scavizzi, F., Raspa, M., Leonetti, C., Falcone, G., Felsani, A. & D’agnano, I., Jun 2020, In: Cancers. 12, 6, p. 1-22 22 p., 1635.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Extracellular Vesicles 100%
  • Heterografts 76%
  • MicroRNAs 71%
  • Melanoma 70%
  • Brain 41%

• Harnessing omics approaches on advanced preclinical models to discovery novel therapeutic targets for the treatment of metastatic colorectal cancer

  Porru, M., Zizza, P., Panera, N., Alisi, A., Biroccio, A. & Leonetti, C., Jul 2020, In: Cancers. 12, 7, p. 1-17 17 p., 1830.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Colorectal Neoplasms 100%
  • Heterografts 56%
  • Theoretical Models 51%
  • Organoids 41%
  • Weapons 39%

• Hybrid lipid self-assembling nanoparticles for brain delivery of microRNA

  Campani, V., Zappavigna, S., Scotti, L., Abate, M., Porru, M., Leonetti, C., Caraglia, M. & De Rosa, G., Oct 15 2020, In: International Journal of Pharmaceutics. 588, p. 119693

  Research output: Contribution to journal › Article › peer-review

  • MicroRNA 100%
  • Glioblastoma 80%
  • Nanoparticles 72%
  • MicroRNAs 68%
  • Lipid 56%

• Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study.

  Bon, G., Pizzuti, L., Laquintana, V., Loria, R., Porru, M., Marchiò, C., Krasniqi, E., Barba, M., Maugeri-Saccà, M., Gamucci, T., Berardi, R., Livi, L., Ficorella, C., Natoli, C., Cortesi, E., Generali, D., La Verde, N., Cassano, A., Bria, E., Moscetti, L. & 30 others, Michelotti, A., Adamo, V., Zamagni, C., Tonini, G., Barchiesi, G., Mazzotta, M., Marinelli, D., Tomao, S., Marchetti, P., Valerio, M. R., Mirabelli, R., Russo, A., Fabbri, M. A., D’Ostilio, N., Veltri, E., Corsi, D., Garrone, O., Paris, I., Sarobba, G., Giotta, F., Garufi, C., Cazzaniga, M., Sanguineti, G., Sperduti, I., Sapino, A., De Maria, R., Leonetti, C., Ciliberto, G., Falcioni, R. & Vici, P., Dec 10 2020, In: Journal of Experimental and Clinical Cancer Research. 39, 1, 279.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • pertuzumab 100%
  • Trastuzumab 46%
  • Breast Neoplasms 40%
  • Ado-Trastuzumab Emtansine 16%
  • Cell Line 8%

• TRF2 and VEGF-A: An unknown relationship with prognostic impact on survival of colorectal cancer patients

  Dinami, R., Porru, M., Amoreo, C. A., Sperduti, I., Mottolese, M., Buglioni, S., Marinelli, D., Maugeri-Saccà, M., Sacconi, A., Blandino, G., Leonetti, C., Di Rocco, G., Verdina, A., Spinella, F., Fiorentino, F., Ciliberto, G., Biroccio, A. & Zizza, P., Jun 15 2020, In: Journal of Experimental and Clinical Cancer Research. 39, 1, 111.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Vascular Endothelial Growth Factor A 100%
  • Colorectal Neoplasms 92%
  • Survival 64%
  • Telomeric Repeat Binding Protein 2 23%
  • Tissue Array Analysis 18%
• 2019

  BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors

  Reisländer, T., Lombardi, E. P., Groelly, F. J., Miar, A., Porru, M., Di Vito, S., Wright, B., Lockstone, H., Biroccio, A., Harris, A., Londoño-Vallejo, A. & Tarsounas, M., Dec 1 2019, In: Nature Communications. 10, 1

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Poly(ADP-ribose) Polymerase Inhibitors 100%
  • inhibitors 87%
  • Cell Death 80%
  • Innate Immunity 69%
  • Mutation 63%

• Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance

  Tacconi, E. M. C., Badie, S., De Gregoriis, G., Reisländer, T., Lai, X., Porru, M., Folio, C., Moore, J., Kopp, A., Baguña Torres, J., Sneddon, D., Green, M., Dedic, S., Lee, J. W., Batra, A. S., Rueda, O. M., Bruna, A., Leonetti, C., Caldas, C., Cornelissen, B. & 4 others, Brino, L., Ryan, A., Biroccio, A. & Tarsounas, M., Jul 2019, In: EMBO Molecular Medicine. 11, 7, p. e9982

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Chlorambucil 100%
  • Poly(ADP-ribose) Polymerase Inhibitors 95%
  • Cisplatin 40%
  • olaparib 27%
  • Neoplasms 23%

• TRF2 positively regulates SULF2 expression increasing VEGF - A release and activity in tumor microenvironment

  Zizza, P., Dinami, R., Porru, M., Cingolani, C., Salvati, E., Rizzo, A., D’Angelo, C., Petti, E., Amoreo, C. A., Mottolese, M., Sperduti, I., Chambery, A., Russo, R., Ostano, P., Chiorino, G., Blandino, G., Sacconi, A., Cherfils-Vicini, J., Leonetti, C., Gilson, E. & 1 others, Biroccio, A., Jan 1 2019, In: Nucleic Acids Research. 47, 7, p. 3365-3382 18 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Tumor Microenvironment 100%
  • N-acetylglucosamine-6-sulfatase 88%
  • Telomeric Repeat Binding Protein 2 88%
  • Vascular Endothelial Growth Factor A 82%
  • Heparan Sulfate Proteoglycans 61%
• 2018

  Adipose-derived stem cell-mediated paclitaxel delivery inhibits breast cancer growth

  Scioli, M. G., Artuso, S., D’Angelo, C., Porru, M., D’Amico, F., Bielli, A., Gentile, P., Cervelli, V., Leonetti, C. & Orlandi, A., Sep 1 2018, In: PLoS One. 13, 9, p. e0203426

  Research output: Contribution to journal › Article › peer-review

  • paclitaxel 100%
  • Paclitaxel 96%
  • breast neoplasms 91%
  • stem cells 79%
  • Conditioned Culture Medium 79%

• Chitosan-based polyelectrolyte complexes for doxorubicin and zoledronic acid combined therapy to overcome multidrug resistance

  Giarra, S., Zappavigna, S., Campani, V., Abate, M., Cossu, A. M., Leonetti, C., Porru, M., Mayol, L., Caraglia, M. & De Rosa, G., Dec 1 2018, In: Pharmaceutics. 10, 4, p. 180

  Research output: Contribution to journal › Article › peer-review

  • Zoledronic Acid 100%
  • Polyelectrolytes 82%
  • Chitosan 62%
  • Multiple Drug Resistance 59%
  • Doxorubicin 59%

• HSP90 Inhibition Drives Degradation of FGFR2 Fusion Proteins: Implications for Treatment of Cholangiocarcinoma

  Lamberti, D., Cristinziano, G., Porru, M., Leonetti, C., Egan, J. B., Shi, C. X., Buglioni, S., Amoreo, C. A., Castellani, L., Borad, M. J., Alemà, S., Anastasi, S. & Segatto, O., Jan 2018, In: Hepatology. 69, 1, p. 131-142 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • STA 9090 100%
  • 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea 85%
  • Receptor, Fibroblast Growth Factor, Type 2 80%
  • HSP90 Heat-Shock Proteins 70%
  • Cholangiocarcinoma 61%

• Targeting kras in metastatic colorectal cancer: Current strategies and emerging opportunities

  Porru, M., Pompili, L., Caruso, C., Biroccio, A. & Leonetti, C., Mar 13 2018, In: Journal of Experimental and Clinical Cancer Research. 37, 1, 57.

  Research output: Contribution to journal › Article › peer-review

  • Oncogenes 100%
  • Colorectal Neoplasms 83%
  • Pharmacology 35%
  • Neoplasms 33%
  • Pharmaceutical Preparations 21%

• Xenograft as in vivo experimental model

  Porru, M., Pompili, L., Caruso, C. & Leonetti, C., Jan 1 2018, Methods in Molecular Biology. Humana Press Inc., p. 97-105 9 p. (Methods in Molecular Biology; vol. 1692).

  Research output: Chapter in Book/Report/Conference proceeding › Chapter

  • Heterografts 100%
  • Theoretical Models 90%
  • Neoplastic Stem Cells 47%
  • Neoplasms 35%
  • Drug Development 21%
• 2017

  BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity

  Tacconi, E. M., Lai, X., Folio, C., Porru, M., Zonderland, G., Badie, S., Michl, J., Sechi, I., Rogier, M., Garcia, V. M., Batra, A. S., Rueda, O. M., Bouwman, P., Jonkers, J., Ryan, A., Reina-San-Martin, B., Hui, J., Tang, N., Bruna, A., Biroccio, A. & 1 others, Tarsounas, M., Oct 1 2017, In: EMBO Molecular Medicine. 9, 10, p. 1398-1414 17 p.

  Research output: Contribution to journal › Article › peer-review

  • Acetaldehyde 100%
  • Homologous Recombination 28%
  • Neoplasms 24%
  • Disulfiram 24%
  • Fanconi Anemia 22%

• EMICORON: A multi-targeting G4 ligand with a promising preclinical profile

  Porru, M., Zizza, P., Franceschin, M., Leonetti, C. & Biroccio, A., May 2017, In: Biochimica et Biophysica Acta - General Subjects. 1861, 5 Pt B, p. 1362-1370 9 p.

  Research output: Contribution to journal › Review article › peer-review

  • EMICORON 100%
  • G-Quadruplexes 29%
  • Ligands 28%
  • coronene 23%
  • Perylene 19%

• Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2

  Gnani, D., Romito, I., Artuso, S., Chierici, M., De Stefanis, C., Panera, N., Crudele, A., Ceccarelli, S., Carcarino, E., D'Oria, V., Porru, M., Giorda, E., Ferrari, K., Miele, L., Villa, E., Balsano, C., Pasini, D., Furlanello, C., Locatelli, F., Nobili, V. & 3 others, Rota, R., Leonetti, C. & Alisi, A., May 1 2017, In: Cell Death and Differentiation. 24, 5, p. 889-902 14 p.

  Research output: Contribution to journal › Article › peer-review

  • Enhancer of Zeste Homolog 2 Protein 100%
  • Focal Adhesion Protein-Tyrosine Kinases 81%
  • Protein-Tyrosine Kinases 59%
  • Hepatocellular Carcinoma 52%
  • Growth 32%

• Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2

  Gnani, D., Romito, I., Artuso, S., Chierici, M., Stefanis, C. D., Panera, N., Crudele, A., Ceccarelli, S., Carcarino, E., D'Oria, V., Porru, M., Giorda, E., Ferrari, K., Miele, L., Villa, E., Balsano, C., Pasini, D., Furlanello, C., Locatelli, F., Nobili, V. & 3 others, Rota, R., Leonetti, C. & Alisi, A., May 1 2017, In: Cell Death and Differentiation. 24, 5, p. 889-902 14 p.

  Research output: Contribution to journal › Article › peer-review

  • Enhancer of Zeste Homolog 2 Protein 100%
  • Focal Adhesion Protein-Tyrosine Kinases 81%
  • Protein-Tyrosine Kinases 59%
  • Hepatocellular Carcinoma 52%
  • Growth 32%

• Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2

  Gnani, D., Romito, I., Artuso, S., Chierici, M., De Stefanis, C., Panera, N., Crudele, A., Ceccarelli, S., Carcarino, E., D'Oria, V., Porru, M., Giorda, E., Ferrari, K., Miele, L., Villa, E., Balsano, C., Pasini, D., Furlanello, C., Locatelli, F., Nobili, V. & 3 others, Rota, R., Leonetti, C. & Alisi, A., May 1 2017, In: Cell Death and Differentiation. 24, 5, p. 889-902 14 p.

  Research output: Contribution to journal › Article › peer-review

  • Enhancer of Zeste Homolog 2 Protein 100%
  • Focal Adhesion Protein-Tyrosine Kinases 81%
  • Protein-Tyrosine Kinases 59%
  • Hepatocellular Carcinoma 52%
  • Growth 32%
• 2016

  EMICORON: A multi-targeting G4 ligand with a promising preclinical profile

  Porru, M., Zizza, P., Franceschin, M., Leonetti, C. & Biroccio, A., Sep 30 2016, (Accepted/In press) In: Biochimica et Biophysica Acta - General Subjects.

  Research output: Contribution to journal › Article › peer-review

  • EMICORON 100%
  • G-Quadruplexes 29%
  • Ligands 28%
  • coronene 23%
  • Perylene 19%

• Intragenic G-quadruplex structure formed in the human CD133 and its biological and translational relevance

  Zizza, P., Cingolani, C., Artuso, S., Salvati, E., Rizzo, A., D'Angelo, C., Porru, M., Pagano, B., Amato, J., Randazzo, A., Novellino, E., Stoppacciaro, A., Gilson, E., Stassi, G., Leonetti, C. & Biroccio, A., Feb 29 2016, In: Nucleic Acids Research. 44, 4, p. 1579-1590 12 p.

  Research output: Contribution to journal › Article › peer-review

  • G-Quadruplexes 100%
  • Neoplastic Stem Cells 72%
  • Alternative Splicing 9%
  • Drug Discovery 8%
  • Introns 8%

• Patient-derived xenografts: A relevant preclinical model for drug development

  Pompili, L., Porru, M., Caruso, C., Biroccio, A. & Leonetti, C., Dec 5 2016, In: Journal of Experimental and Clinical Cancer Research. 35, 1, 189.

  Research output: Contribution to journal › Review article › peer-review

  • Drug Development 100%
  • Heterografts 94%
  • Neoplasms 34%
  • Pharmaceutical Preparations 14%
  • Therapeutics 5%

• Targeting BRCA1 and BRCA2 Deficiencies with G-Quadruplex-Interacting Compounds

  Zimmer, J., Tacconi, E. M. C., Folio, C., Badie, S., Porru, M., Klare, K., Tumiati, M., Markkanen, E., Halder, S., Ryan, A., Jackson, S. P., Ramadan, K., Kuznetsov, S. G., Biroccio, A., Sale, J. E. & Tarsounas, M., Feb 4 2016, In: Molecular Cell. 61, 3, p. 449-460 12 p.

  Research output: Contribution to journal › Article › peer-review

  • G-Quadruplexes 100%
  • Homologous Recombination 77%
  • pyridostatin 63%
  • Telomere 42%
  • compound G4 21%

• Transferrin-targeted nanoparticles containing zoledronic acid as a potential tool to inhibit glioblastoma growth

  Salzano, G., Zappavigna, S., Luce, A., D'Onofrio, N., Balestrieri, M. L., Grimaldi, A., Lusa, S., Ingrosso, D., Artuso, S., Porru, M., Leonetti, C., Caraglia, M. & De Rosa, G., Apr 1 2016, In: Journal of Biomedical Nanotechnology. 12, 4, p. 811-830 20 p.

  Research output: Contribution to journal › Article › peer-review

  • Zoledronic Acid 100%
  • Transferrin 61%
  • Glioblastoma 56%
  • Nanoparticles 55%
  • Acids 51%